Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA appropriation stalls

This article was originally published in The Tan Sheet

Executive Summary

The House Appropriations Committee postpones a markup of fiscal 2011 agriculture funding legislation, leaving FDA funding in limbo. The House adjourned for August recess without taking action, leaving fiscal 2011 funding levels undetermined until Congress returns the week of Sept. 13. With all House members and some of the Senate soon to focus on elections, chances are growing for an omnibus bill or continuing resolution to fund federal agencies at the start of the next fiscal year (1"The Tan Sheet" July 26, 2010)

You may also be interested in...

FDA Funding Not Set As Chances Grow For Omnibus Or Continuing Resolution

FDA's fiscal 2011 funding is not the only decision Congress has yet to make - lawmakers likely will face passing either an omnibus spending bill or a continuing resolution to keep the federal government operating past the end of the current fiscal year

Refillable Personal-Care Packaging: Experts Discuss Contamination Risks, Liability, MoCRA Compliance

Personal-care companies navigating a growing patchwork of state recycling laws are exploring refillable packaging options, but there are serious concerns and questions to consider before embarking down this potentially risky path, experts said at IBA’s Supply Chain & Sustainability Conference.

Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment

The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts